InMode Reports Sharp Decline in FY2025 Net Income Amidst Revenue Drop and Ongoing Lawsuit
summarizeSummary
InMode Ltd. reported a significant decrease in net income and revenue for fiscal year 2025, alongside an update on a shareholder class action lawsuit and heightened geopolitical risk disclosures.
check_boxKey Events
-
Substantial Profitability Decline
Net income for fiscal year 2025 fell by 48.2% to $93.8 million from $181.3 million in fiscal year 2024. Operating income also decreased by 24% to $85.4 million.
-
Revenue Contraction
Total revenue for fiscal year 2025 decreased by 6% to $370.5 million, primarily driven by an 18.9% decline in U.S. sales due to a slowdown in aesthetic procedures and a challenging financing market.
-
Ongoing Shareholder Lawsuit
The company is actively defending against a shareholder class action lawsuit alleging false or misleading statements, with a motion to dismiss the second amended complaint filed in December 2025.
-
Heightened Geopolitical Risk
Updated risk factors detail the impact of the Israel-Hamas war and regional escalations, including potential disruptions to operations and employee military service.
auto_awesomeAnalysis
InMode Ltd.'s annual report reveals a challenging fiscal year 2025, marked by a substantial 48.2% drop in net income and a 6% decline in overall revenue. The significant downturn in U.S. sales, attributed to a slowdown in aesthetic procedures and a difficult financing environment, is a key concern. Investors should note the ongoing shareholder class action lawsuit, which poses a material legal risk, and the detailed geopolitical risk factors related to the Israel-Hamas war and regional instability, which could further impact operations. While new product introductions offer some long-term potential, the immediate financial performance and external risks present a negative outlook for the company.
At the time of this filing, INMD was trading at $14.61 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $955.7M. The 52-week trading range was $13.14 to $19.78. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.